ACHE and early-onset autosomal dominant Alzheimer disease: In this line, the acetylcholinesterase inhibitor rivastigmine reversed the abnormality of sensorimotor integration, as evaluated by testing short-latency afferent inhibition, in patients affected by Alzheimer’s disease (Di Lazzaro et al., 2005).